{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:56:36Z","timestamp":1791618996742,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019492","name":"National Natural Science Foundation of China-China Academy of General Technology Joint Fund for Basic Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Thrombopoietin receptor agonists (TPO-RAs) play a crucial role in stimulating thrombopoiesis. However, conventional meta-analyses have shown inconsistent results regarding the efficacy of thrombopoietin receptor agonists versus placebo. Therefore, we performed a network meta-analysis to assess the effects of five TPO-RAs\n                    <jats:italic>via<\/jats:italic>\n                    indirect comparison. For this network meta-analysis, we considered randomized trials that included any of the following interventions: avatrombopag, lusutrombopag, eltrombopag, romiplostim, recombinant human thrombopoietin (rhTPO). We searched the\n                    <jats:italic>Medline<\/jats:italic>\n                    ,\n                    <jats:italic>PubMed<\/jats:italic>\n                    ,\n                    <jats:italic>Embase<\/jats:italic>\n                    ,\n                    <jats:italic>the Cochrane Library<\/jats:italic>\n                    , and\n                    <jats:italic>Web of Science<\/jats:italic>\n                    databases for randomized controlled clinical trials from inception to January 31, 2021. We use randomized controlled clinical trials of TPO-RAs for treatment of immune thrombocytopenia in adults. The primary outcome was the number of patients achieving platelet response which was defined as the achievement of a platelet count of more than 30 or 50 cells \u00d7 10\n                    <jats:sup>9<\/jats:sup>\n                    \/L in the absence of rescue therapy, and the secondary outcome was the therapy-related serious adverse events and incidence of bleeding episodes. To obtain the estimates of efficacy and safety outcomes, we performed a random-effects network meta-analysis. These estimates were presented as odds ratios with 95% confidence intervals. We use surface under the cumulative ranking probabilities to rank the comparative effects and safety of all drugs against the placebo. In total, 2,207 patients were analyzed in 20 clinical trials. All preparations improved the point estimates of platelet response when compared with the placebo. Avatrombopag and lusutrombopag had the best platelet response compared to the placebo, the former had a non-significant advantage compared to the latter [odds ratio (OR) = 1.91 (95% confidence interval: 0.52, 7.05)]. The treatments were better than eltrombopag, romiplostim, rituximab, and rhTPO + rituximab, with corresponding ORs of 3.10 (1.01, 9.51), 9.96 (2.29, 43.29), 33.09 (8.76, 125.02), and 21.31 (3.78, 119.98) for avatrombopag and 1.62 (0.63, 4.17), 5.21 (1.54, 17.62), 17.34 (5.15, 58.36), and 11.16 (2.16, 57.62) for lusutrombopag. Regarding bleeding, the placebo group had the highest probability of bleeding, whereas lusutrombopag had the lowest risk of bleeding when compared to the placebo. Adverse events were slightly higher in patients receiving rituximab than in those receiving placebo or other treatments. Overall, this meta-analysis showed that avatrombopag may yield the highest efficacy because it has the most favorable balance of benefits and acceptability.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.704093","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T04:41:14Z","timestamp":1627447274000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Junzhu","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feihong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anguo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJMoa1110709","article-title":"Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia","volume":"367","author":"Afdhal","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1182\/blood-2011-08-374777","article-title":"A Pilot Randomized Trial of Adjuvant Rituximab or Placebo for Nonsplenectomized Patients with Immune Thrombocytopenia","volume":"119","author":"Arnold","year":"2012","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","article-title":"A Randomized Trial of Avatrombopag, an Investigational Thrombopoietin-Receptor Agonist, in Persistent and Chronic Immune Thrombocytopenia","volume":"123","author":"Bussel","year":"2014","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/s0140-6736(09)60402-5","article-title":"Effect of Eltrombopag on Platelet Counts and Bleeding during Treatment of Chronic Idiopathic Thrombocytopenic Purpura: a Randomised, Double-Blind, Placebo-Controlled Trial","volume":"373","author":"Bussel","year":"2009","journal-title":"The Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s0140-6736(10)60959-2","article-title":"Eltrombopag for Management of Chronic Immune Thrombocytopenia (RAISE): a 6-month, Randomised, Phase 3 Study","volume":"377","author":"Cheng","year":"2011","journal-title":"The Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune Thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and Technical Challenges in Network Meta-Analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/moh.0000000000000270","article-title":"Controversies in the Treatment of Immune Thrombocytopenia","volume":"23","author":"Cuker","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/ejh.12777","article-title":"Thromboembolism in Adults with Primary Immune Thrombocytopenia: a Systematic Literature Review and Meta-Analysis","volume":"97","author":"Doobaree","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/s0140-6736(14)61495-1","article-title":"Rituximab as Second-Line Treatment for Adult Immune Thrombocytopenia (The RITP Trial): a Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"The Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cgh.2018.11.047","article-title":"Lusutrombopag Reduces Need for Platelet Transfusion in Patients with Thrombocytopenia Undergoing Invasive Procedures","volume":"17","author":"Hidaka","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3760\/cma.j.issn.0253-2727.2018.01.007","article-title":"[The Efficacy and Safety of Eltrombopag in Chinese Patients with Chronic Immune Thrombocytopenia]","volume":"39","author":"Huang","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"B14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 Randomised Study of Avatrombopag, a Novel Thrombopoietin Receptor Agonist for the Treatment of Chronic Immune Thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/bor.0000000000000599","article-title":"Treatment of Primary and Secondary Immune Thrombocytopenia","volume":"31","author":"Kado","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40265-015-0525-4","article-title":"Lusutrombopag: First Global Approval","volume":"76","author":"Kim","year":"2016","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjh.15574","article-title":"Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double-Blind, Dose-Rising, Placebo-Controlled Phase 1 Studies","volume":"183","author":"Kuter","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/s0140-6736(08)60203-2","article-title":"Efficacy of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura: a Double-Blind Randomised Controlled Trial","volume":"371","author":"Kuter","year":"2008","journal-title":"The Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical Updates in Adult Immune Thrombocytopenia","volume":"129","author":"Lambert","year":"2017","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.thromres.2017.05.010","article-title":"Epidemiology and Management of Primary Immune Thrombocytopenia: A Nationwide Population-Based Study in Korea","volume":"155","author":"Lee","year":"2017","journal-title":"Thromb. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 Evidence-Based Practice Guideline for Immune Thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/hep.30561","article-title":"Lusutrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2)","volume":"70","author":"Peck-Radosavljevic","year":"2019","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a Thrombophilic Disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am. J. Hematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1182\/blood.v104.11.2063.2063","article-title":"Pharmacology and Safety of SB-497115-GR, an Orally Active Small Molecular Weight TPO Receptor Agonist, in Chimpanzees, Rats and Dogs","volume":"104","author":"Sellers","year":"2004","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e2017047","DOI":"10.4178\/epih.e2017047","article-title":"Network Meta-Analysis: Application and Practice Using Stata","volume":"39","author":"Shim","year":"2017","journal-title":"Epidemiol. Heal."},{"key":"B27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12185-011-0886-8","article-title":"Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Adult Japanese Patients: a Double-Blind, Randomized Phase III Clinical Trial","volume":"94","author":"Shirasugi","year":"2011","journal-title":"Int. J. Hematol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s40265-018-0949-8","article-title":"Avatrombopag: First Global Approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00535-018-1499-2","article-title":"A Randomized Controlled Trial of Lusutrombopag in Japanese Patients with Chronic Liver Disease Undergoing Radiofrequency Ablation","volume":"54","author":"Tateishi","year":"2019","journal-title":"J. Gastroenterol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","article-title":"Avatrombopag before Procedures Reduces Need for Platelet Transfusion in Patients with Chronic Liver Disease and Thrombocytopenia","volume":"155","author":"Terrault","year":"2018","journal-title":"Gastroenterology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1538-7836.2012.04695.x","article-title":"A Lower Starting Dose of Eltrombopag Is Efficacious in Japanese Patients with Previously Treated Chronic Immune Thrombocytopenia","volume":"10","author":"Tomiyama","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"B32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and Pharmacokinetics of AMG 531, a Novel Thrombopoietin Receptor Ligand","volume":"76","author":"Wang","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and Inconsistency in Network Meta\u2010analysis: Model Estimation Using Multivariate Meta\u2010regression","volume":"3","author":"White","year":"2012","journal-title":"Res. Syn. Meth."},{"key":"B34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bjh.14380","article-title":"Multicentre, Randomised Phase III Study of the Efficacy and Safety of Eltrombopag in Chinese Patients with Chronic Immune Thrombocytopenia","volume":"176","author":"Yang","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/16078454.2019.1568659","article-title":"Therapeutic Options for Adult Patients with Previously Treated Immune Thrombocytopenia - a Systematic Review and Network Meta-Analysis","volume":"24","author":"Yang","year":"2019","journal-title":"Hematology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"Cd012035","DOI":"10.1002\/14651858.CD012035.pub2","article-title":"Thrombopoietin Receptor Agonists for Prevention and Treatment of Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumours","volume":"2017","author":"Zhang","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood-2014-06-581868","article-title":"A Multicenter Randomized Open-Label Study of Rituximab Plus rhTPO vs Rituximab in Corticosteroid-Resistant or Relapsed ITP","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.704093\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T04:41:19Z","timestamp":1627447279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.704093\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":37,"alternative-id":["10.3389\/fphar.2021.704093"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.704093","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]},"article-number":"704093"}}